Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

H102

Supelco

Haloperidol metabolite II

analytical standard

Synonyma:

(±)-4-(4-Chlorophenyl)-α-(4-fluorophenyl)-4-hydroxy-1-piperidinebutanol, Reduced Haloperidol

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

Empirický vzorec (Hillův zápis):
C21H25ClFNO2
Číslo CAS:
Molekulová hmotnost:
377.88
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

analytical standard

Quality Level

assay

≥98% (HPLC)

form

solid

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

color

white

solubility

DMSO: 10 mg/mL

application(s)

forensics and toxicology
pharmaceutical (small molecule)
veterinary

format

neat

SMILES string

OC(CCCN1CCC(O)(CC1)c2ccc(Cl)cc2)c3ccc(F)cc3

InChI

1S/C21H25ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,20,25-26H,1-2,11-15H2

InChI key

WNZBBTJFOIOEMP-UHFFFAOYSA-N

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Nevidíte správnou verzi?

Potřebujete-li konkrétní verzi, můžete vyhledat daný certifikát podle čísla dávky nebo čísla šarže.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

L Pan et al.
European journal of clinical pharmacology, 55(8), 599-604 (1999-12-14)
To investigate in vitro which CYP isoforms (CYP1A2, CYP2D6 and CYP3A4) are involved in the biotransformation of haloperidol (HAL) and reduced haloperidol (RHAL). The biotransformation of HAL and RHAL is evaluated by measuring HAL and RHAL remaining after incubation with
M S Lee et al.
Psychiatry and clinical neurosciences, 52 Suppl, S193-S198 (1999-01-23)
Along with recent increased interest in the selective serotonin reuptake inhibitors, a number of studies has been undertaken to observe interactions with different drugs. When selective serotonin reuptake inhibitor was administered together with antipsychotics to schizophrenics showing depressive or obsessive
D W Eyles et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 8(2), 127-129 (1998-06-10)
In vitro, cytosolic human ketone reductases catalyse the stereospecific (i.e. >99%) formation of S(-) reduced haloperidol (RHP) from haloperidol (HP). Whether this situation is reflected in patients taking the drug is unknown. In this study in nine patients taking HP
W H Chang et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 4(2), 119-126 (1994-06-01)
Plasma haloperidol (HL) and reduced haloperidol (RH) levels were measured in 60 schizophrenic patients treated with high to very high HL doses of 40-200 mg/day. Plasma samples were obtained at steady-state conditions and 10-12 h after the evening dose and
Naoya Kishikawa et al.
Analytical and bioanalytical chemistry, 386(3), 719-724 (2006-09-08)
A simultaneous method for the determination of haloperidol (HP) and its metabolite, reduced haloperidol (RHP), in human serum was developed by means of high-performance liquid chromatography (HPLC) with fluorescence detection. Suzuki coupling reaction with a fluorescent arylboronic acid, 4-(4,5-diphenyl-1H-imidazol-2-yl)phenylboronic acid

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.